Keywords: cv, therapeutics, ph, ii, cvt-124, data, phase

CV Therapeutics, Ph II CVT-124 Data

Article | 04 June 1998

Print This

Data from a Phase II trial of CV Therapeutics' adenosine A1receptor antagonist CVT-124 have shown that the compound was ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in